Match!

High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: Results of the MOSCATO 01 trial

Published on Jun 1, 2017in Cancer Discovery26.37
· DOI :10.1158/2159-8290.CD-16-1396
Christophe Massard31
Estimated H-index: 31
(Université Paris-Saclay),
Christophe Massard36
Estimated H-index: 36
(Université Paris-Saclay)
+ 30 AuthorsJean-Charles Soria72
Estimated H-index: 72
(Université Paris-Saclay)
Sources
Abstract
High-throughput genomic analyses may improve outcomes in patients with advanced cancers. MOSCATO 01 is a prospective clinical trial evaluating the clinical benefit of this approach. Nucleic acids were extracted from fresh-frozen tumor biopsies and analyzed by array comparative genomic hybridization, next-generation sequencing, and RNA sequencing. The primary objective was to evaluate clinical benefit as measured by the percentage of patients presenting progression-free survival (PFS) on matched therapy (PFS2) 1.3-fold longer than the PFS on prior therapy (PFS1). A total of 1,035 adult patients were included, and a biopsy was performed in 948. An actionable molecular alteration was identified in 411 of 843 patients with a molecular portrait. A total of 199 patients were treated with a targeted therapy matched to a genomic alteration. The PFS2/PFS1 ratio was >1.3 in 33% of the patients (63/193). Objective responses were observed in 22 of 194 patients (11%; 95% CI, 7%–17%), and median overall survival was 11.9 months (95% CI, 9.5–14.3 months). Significance: This study suggests that high-throughput genomics could improve outcomes in a subset of patients with hard-to-treat cancers. Although these results are encouraging, only 7% of the successfully screened patients benefited from this approach. Randomized trials are needed to validate this hypothesis and to quantify the magnitude of benefit. Expanding drug access could increase the percentage of patients who benefit. Cancer Discov; 7(6); 586–95. ©2017 AACR. See related commentary by Schram and Hyman, p. 552 . This article is highlighted in the In This Issue feature, p. 539
Figures & Tables
  • References (31)
  • Citations (181)
📖 Papers frequently viewed together
451 Citations
358 Citations
311 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References31
Newest
#1Fabrice Andre (Université Paris-Saclay)H-Index: 79
#2Sara A. Hurvitz (UCLA: University of California, Los Angeles)H-Index: 37
Last. Dennis J. Slamon (UCLA: University of California, Los Angeles)H-Index: 54
view all 16 authors...
PurposeTwo recent phase III trials, BOLERO-1 and BOLERO-3 (Breast Cancer Trials of Oral Everolimus), evaluated the addition of everolimus to trastuzumab and chemotherapy in human epidermal growth factor receptor 2–overexpressing advanced breast cancer. The current analysis aimed to identify biomarkers to predict the clinical efficacy of everolimus treatment.MethodsArchival tumor samples from patients in BOLERO-1 and BOLERO-3 were analyzed using next-generation sequencing, immunohistochemistry, a...
75 CitationsSource
#1Gabriel N. Hortobagyi (University of Texas MD Anderson Cancer Center)H-Index: 13
#1Gabriel N. Hortobagyi (University of Texas MD Anderson Cancer Center)H-Index: 144
Last. José Baselga (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 143
view all 25 authors...
PurposeTo explore the genetic landscape of tumors from patients enrolled on the BOLERO-2 trial to identify potential correlations between genetic alterations and efficacy of everolimus treatment. The BOLERO-2 trial has previously demonstrated that the addition of everolimus to exemestane prolonged progression-free survival by more than twofold in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer previously treated with nonsteroidal...
106 CitationsSource
#1Charles Swanton (Francis Crick Institute)H-Index: 71
#2Jean-Charles Soria (French Institute of Health and Medical Research)H-Index: 72
Last. Fabrice Andre (French Institute of Health and Medical Research)H-Index: 79
view all 19 authors...
Recent advances in biotechnologies have led to the development of multiplex genomic and proteomic analyses for clinical use. Nevertheless, guidelines are currently lacking to determine which molecular assays should be implemented in metastatic cancers. The first MAP conference was dedicated to exploring the use of genomics to better select therapies in the treatment of metastatic cancers. Sixteen consensus items were covered. There was a consensus that new technologies like next-generation seque...
45 CitationsSource
#1Jennifer J. Wheler (University of Texas MD Anderson Cancer Center)H-Index: 33
#2Filip Janku (University of Texas MD Anderson Cancer Center)H-Index: 45
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 19 authors...
Innovative molecular diagnostics deployed in the clinic enable new ways to stratify patients into appropriate treatment regimens. These approaches may resolve a major challenge for early-phase clinical trials, which is to recruit patients who, while having failed previous treatments, may nevertheless respond to molecularly-targeted drugs. We report the findings of a prospective, single-center study conducted in patients with diverse refractory cancers who underwent comprehensive genomic profilin...
87 CitationsSource
#1S. Postel-VinayH-Index: 5
#2Yannick Boursin (French Institute of Health and Medical Research)H-Index: 6
Last. J.-C. SoriaH-Index: 2
view all 14 authors...
Molecular tumour profiling technologies have become increasingly important in the era of precision medicine, but their routine use is limited by their accessibility, cost, and tumour material availability. It is therefore crucial to assess their relative added value to optimize the sequence and combination of such technologies.Within the MOSCATO-01 trial, we investigated the added value of whole exome sequencing (WES) in patients that did not present any molecular abnormality on array comparativ...
7 CitationsSource
#1Christophe Le Tourneau (Curie Institute)H-Index: 33
#2Jean-Pierre DelordH-Index: 33
Last. Xavier Paoletti (Curie Institute)H-Index: 32
view all 23 authors...
451 CitationsSource
#1David M. Hyman (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 45
#2Igor Puzanov (VUMC: Vanderbilt University Medical Center)H-Index: 55
Last. José Baselga (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 143
view all 23 authors...
BackgroundBRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation–positive nonmelanoma cancers. MethodsWe enrolled patients in six prespecified cancer cohorts; patients with all other tumor types were enrolled in a seventh cohort. A total of 122 patients with BRAF V600 mutation–positive cancer were treated, including 27 patients with colorectal cancer who received vemurafenib and cetuximab. The pri...
752 CitationsSource
#1Himisha Beltran (Cornell University)H-Index: 43
#2Kenneth Eng (Cornell University)H-Index: 8
Last. Mark Raffeld (Cornell University)H-Index: 91
view all 44 authors...
Importance Understanding molecular mechanisms of response and resistance to anticancer therapies requires prospective patient follow-up and clinical and functional validation of both common and low-frequency mutations. We describe a whole-exome sequencing (WES) precision medicine trial focused on patients with advanced cancer. Objective To understand how WES data affect therapeutic decision making in patients with advanced cancer and to identify novel biomarkers of response. Design, Setting, and...
148 CitationsSource
#1Funda Meric-Bernstam (University of Texas MD Anderson Cancer Center)H-Index: 80
#2Lauren Brusco (University of Texas MD Anderson Cancer Center)H-Index: 10
Last. Gordon B. Mills (University of Texas MD Anderson Cancer Center)H-Index: 157
view all 19 authors...
196 CitationsSource
#1Fabrice Andre (French Institute of Health and Medical Research)H-Index: 79
#2Elaine R. Mardis (WashU: Washington University in St. Louis)H-Index: 134
Last. Charles Swanton (London Research Institute)H-Index: 71
view all 6 authors...
The implementation of cancer genomic testing into the clinical setting has brought major opportunities. However, as our understanding of cancer initiation, maintenance and progression improves through detailed cancer genomic studies, the challenges associated with driver identification and target classification in the clinical setting become clearer. Here, we review recent insights into cancer genomic testing in the clinical setting, and suggest a target classification approach that considers th...
71 CitationsSource
Cited By181
Newest
#1S. Coquerelle (French Institute of Health and Medical Research)H-Index: 1
#2Meryl DarlingtonH-Index: 3
Last. Isabelle Durand-Zaleski (French Institute of Health and Medical Research)H-Index: 30
view all 9 authors...
Abstract Objectives We evaluated how next generation sequencing (NGS) can modify care pathways in an observational impact study in France. Methods All patients with lung cancer, colorectal cancer, or melanoma who had NGS analyses of somatic genomic alterations done in 1 of 7 biomolecular platforms certified by the French National Cancer Institute (INCa) between 2013 and 2016 were eligible. We compared patients’ pathways before and after their NGS results. Endpoints consisted of the turnaround ti...
Source
#1Pritam TayshetyeH-Index: 1
#2Katherine MillerH-Index: 3
Last. Gene Grant FinleyH-Index: 8
view all 6 authors...
Source
#2Laurent Holtzer (Philips)H-Index: 1
Last. Jules P.P. MeijerinkH-Index: 35
view all 8 authors...
The Notch signal transduction pathway is pivotal for various physiological processes including immune responses, and has been implicated in the pathogenesis of many diseases including T-cell acute lymphoblastic leukemia. Various targeted drugs are available that inhibit Notch pathway signaling, but their effectiveness varies due to variable Notch pathway activity among individual patients. Quantitative measurement of Notch pathway activity is therefore essential to identify patients who could be...
Source
#2Uwe Haberkorn (DKFZ: German Cancer Research Center)H-Index: 66
New scientific insights in cancer biology and immunobiology have changed the clinical practice of medical oncology in recent years. The molecular stratification of solid tumors has led to improved clinical outcomes and is a key part in the diagnostic workup. Beyond mutational spectra (like Rat sarcoma [RAS] mutations or tumor mutational burden), the investigation of the immunological microenvironment has attracted more efforts. Especially as immunotherapies have changed the standard treatment fo...
Source
#1Nicole M. Iñiguez-Ariza (Mayo Clinic)H-Index: 7
#2Sina Jasim (WashU: Washington University in St. Louis)H-Index: 9
Last. Constanza Alcaino (Mayo Clinic)H-Index: 5
view all 11 authors...
CONTEXT: Clinical applications of genomic assessment of thyroid cancers are rapidly evolving. OBJECTIVES, DESIGN AND SETTING: We studied tumor samples from patients with imminently threatening and rare thyroid cancers to identify genomic alterations that might correlate with outcomes and/or be productively therapeutically targetable. PATIENT CONTEXT: Progressive and metastatic, and/or rare, thyroid cancers, 2012-2016, Mayo Clinic sites. INTERVENTION: Foundation One TM tumor interrogation. MAIN O...
Source
#1Angélique VienotH-Index: 4
#2Cindy Neuzillet (Curie Institute)H-Index: 6
Last. Cindy NeuzilletH-Index: 17
view all 2 authors...
Summary Biliary tract cancers (BTC) are a heterogeneous group of epithelial neoplasms, with a poor prognosis. Advanced BTC remains a challenging, non-curable disease. In this review, we provide an overview of the medical treatment options in advanced BTC and new strategies under development. Gemcitabine plus platinum chemotherapy is the standard first-line therapy in this setting. Recently, 5-fluorouracil, folinic acid plus oxaliplatin (FOLFOX) regimen became the only second-line therapy to be p...
Source
#1Raunak Shrestha (UBC: University of British Columbia)H-Index: 7
#2Marta Llaurado Fernandez (UBC: University of British Columbia)H-Index: 3
Last. Shane Colborne (BC Cancer Agency)H-Index: 3
view all 18 authors...
Low-grade serous ovarian carcinoma (LGSOC) is a rare tumor subtype with high case fatality rates. As such, there is a pressing need to develop more effective treatments using newly available preclinical models for therapeutic discovery and drug evaluation. Here, we use a multiomics approach to interrogate a collection of LGSOC patient-derived cell lines to elucidate novel biomarkers and therapeutic vulnerabilities. Fourteen LGSOC cell lines were interrogated using whole exome sequencing, RNA seq...
Source
#1Nicola NormannoH-Index: 57
#2Massimo Barberis (IEO: European Institute of Oncology)H-Index: 27
Last. Cesare GridelliH-Index: 49
view all 4 authors...
The identification of the optimal cancer treatment has become progressively more intricate for non-small-cell lung cancer (NSCLC) patients due to the multitude of options available. The testing of biomarkers to predict clinical responses to therapies is pivotal to stratify the patients based on the molecular features of their tumors. The number of actionable genetic alterations to be tested is increasing together with the comprehension of the molecular mechanisms underlying tumor growth and deve...
Source
#1F. Facchinetti (Institut Gustave Roussy)H-Index: 4
#2Ludovic LacroixH-Index: 44
Last. Stefan MichielsH-Index: 52
view all 19 authors...
INTRODUCTION: BRAF is a confirmed therapeutic target in non-small cell lung cancer (NSCLC), as the BRAF inhibitor dabrafenib, in combination with the MEK inhibitor trametinib, is approved for the treatment of NSCLC harbouring BRAF V600E mutation. Scant evidence is available concerning the mechanisms of resistance to BRAF/MEK inhibitors in BRAF(V600E) NSCLC. PATIENTS AND METHODS: Patients with BRAF(V600E) NSCLC with acquired resistance to BRAF/MEK inhibitors were included in the institutional, pr...
Source
#1Ute Goerling (Humboldt University of Berlin)H-Index: 8
#2Amy RohrmoserH-Index: 2
Last. Peter HerschbachH-Index: 31
view all 6 authors...
Die Prazisionsonkologie ist fur betroffene Patienten mit grosen Hoffnungen auf einen Therapieerfolg verbunden. Die Datenlage zu klinischem Nutzen von prazisionsonkologischen Ansatzen ist uneinheitlich und die Komplexitat der Thematik stellt hohe Anforderungen an das Patientenverstandnis. Die Fuhrung dieser Patienten stellt neue Herausforderungen an die behandelnden Onkologen. Dieser Beitrag berichtet den aktuellen Stand der psychoonkologischen Forschung zu den psychosozialen Belastungen dieser P...
Source